8-(2-methoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one | 443326-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-(2-methoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one
• 英文别名: 8-(2-methoxyphenyl)-7,8-dihydro[1,3]dioxolo[4,5-g]quinolin-6(5H)-one；8-(2-methoxyphenyl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]quinolin-6-one
• CAS: 443326-13-4
• 化学式: C₁₇H₁₅NO₄
• 分子量: 297.31
• InChiKey: HIEYVTSQMLHJEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-(2-methoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one 在 diphosphorus pentasulfide 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 6.0h， 生成 C₁₇H₁₅NO₃S
  参考文献：
  名称：

  [EN] [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER
  [FR] DÉRIVÉS DE [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE ET DE [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE COMME INHIBITEURS DU FACTEUR TARDIF DE TRANSCRIPTION DE SV40 (LSF) POUR L'UTILISATION DANS LE TRAITEMENT DU CANCER

  摘要：

  本发明涉及一般性地 [l,3]二噁英并[4,5-g]喹啉-6(5H)硫醇和[l,3]二噁英并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物和/或组合物的使用，用于抑制、预防和/或治疗癌症，例如肝细胞癌（HCC）。在某些实施例中，本发明涉及使用小分子化合物抑制、预防和/或治疗转录因子晚期SV40因子（LSF）的表达，用于治疗HCC或其他癌症类型。

  公开号：

  WO2013052465A1
• 作为产物：
  描述：

  3,4-亚甲二氧基苯胺 、 6,6-dimethyldihydro-2H-pyran-2,4(3H)-dione 、 邻甲氧基苯甲醛 在 ziconium(IV) oxychloride octahydrate 作用下， 以 neat (no solvent) 为溶剂， 反应 0.58h， 以84%的产率得到8-(2-methoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one
  参考文献：
  名称：

  ZrOCl₂ · 8H₂O: An Efficient, Ecofriendly, and Recyclable Catalyst for Ultrasound-Accelerated, One-Pot, Solvent-Free Synthesis of 8-Aryl-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6-(5H)-one and 4-Aryl-3,4-dihydroquinolin-2(1 H)-one Derivatives

  摘要：

  A convenient, one-pot, solvent-free reaction of amines, aromatic aldehydes, and Meldrum's acid to form 8-aryl-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6-(5H)-one and 4-aryl-3,4-dihydroquinolin-2-(1H)-one in the presence of 10mol% ZrOCl2.8H(2)O under ultrasonic irradiation is described. This new protocol offers several advantages including low catalyst loading, clean reaction, easy workup, use of recyclable and ecofriendly catalyst, short reaction times, good yields, and solvent-free conditions. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) to view the free supplemental file.

  DOI：

  10.1080/00397911.2012.718026

文献信息

• Compounds, compositions and methods of inhibiting a-synuclein toxicity
  申请人：The Whitehead Institute for Biomedical Research

  公开号：EP2433634A2

  公开（公告）日：2012-03-28

  Compounds and compositions are provided for treatment or amelioration of one or more symptoms of a-synuclein toxicity, a-synuclein mediated diseases or diseases in which a-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihydropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles.

  提供的化合物和组合物用于治疗或改善a-突触核蛋白毒性、a-突触核蛋白介导的疾病或a-突触核蛋白纤维是症状或病因的疾病的一种或多种症状。在一个实施方案中，用于组合物和方法的化合物是杂芳基酰基胍、杂芳基肼、二氢吡啶酮、杂芳基和芳基苯乙烯基酮以及杂芳基吡唑。
• Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US10392398B2

  公开（公告）日：2019-08-27

  The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III′) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.

  本发明涉及治疗癌症，例如七细胞癌的方法、组合物和试剂盒。在一些实施方案中，本发明公开了本文所公开的式(I)-(XXVI)和(III′)的小分子化合物用于抑制转录因子晚期SV40因子(LSF)以治疗癌症，例如HCC。
• Azarifar, Davood; Sheikh, Davood, Acta Chimica Slovenica, 2012, vol. 59, # 3, p. 664 - 669,6
  作者：Azarifar, Davood、Sheikh, Davood

  DOI：——

  日期：——
• INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US20170044175A1

  公开（公告）日：2017-02-16

  The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III′) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
• US8440705B2
  申请人：——

  公开号：US8440705B2

  公开（公告）日：2013-05-14